Your browser doesn't support javascript.
Design, synthesis and immunological evaluation of monophosphoryl lipid A derivatives as adjuvants for a RBD-hFc based SARS-CoV-2 vaccine.
Su, Shiwei; Chen, Liqing; Yang, Menglan; Liang, Dan; Ke, Bixia; Liu, Zhongqiu; Ke, Changwen; Liao, Guochao; Liu, Liang; Luo, Xiang.
  • Su S; Joint Laboratory for Translational Cancer Research of Chinese Medicine of the Ministry of Education of the People's Republic of China, International Institute for Translational Chinese Medicine, Guangzhou University of Chinese Medicine Guangzhou China liao@gzucm.edu.cn luoxiang@gzucm.edu.cn.
  • Chen L; Joint Laboratory for Translational Cancer Research of Chinese Medicine of the Ministry of Education of the People's Republic of China, International Institute for Translational Chinese Medicine, Guangzhou University of Chinese Medicine Guangzhou China liao@gzucm.edu.cn luoxiang@gzucm.edu.cn.
  • Yang M; State Key Laboratory of Dampness Syndrome of Chinese Medicine, The Second Affiliated Hospital of Guangzhou University of Chinese Medicine Guangzhou China lliu@gzucm.edu.cn.
  • Liang D; Joint Laboratory for Translational Cancer Research of Chinese Medicine of the Ministry of Education of the People's Republic of China, International Institute for Translational Chinese Medicine, Guangzhou University of Chinese Medicine Guangzhou China liao@gzucm.edu.cn luoxiang@gzucm.edu.cn.
  • Ke B; Guangdong Provincial Center for Disease Control and Prevention Guangzhou China.
  • Liu Z; Guangdong Provincial Center for Disease Control and Prevention Guangzhou China.
  • Ke C; Joint Laboratory for Translational Cancer Research of Chinese Medicine of the Ministry of Education of the People's Republic of China, International Institute for Translational Chinese Medicine, Guangzhou University of Chinese Medicine Guangzhou China liao@gzucm.edu.cn luoxiang@gzucm.edu.cn.
  • Liao G; Guangdong Provincial Center for Disease Control and Prevention Guangzhou China.
  • Liu L; Joint Laboratory for Translational Cancer Research of Chinese Medicine of the Ministry of Education of the People's Republic of China, International Institute for Translational Chinese Medicine, Guangzhou University of Chinese Medicine Guangzhou China liao@gzucm.edu.cn luoxiang@gzucm.edu.cn.
  • Luo X; Guangdong Hengda Biomedical Technology Co., Ltd. Guangzhou China.
RSC Med Chem ; 14(1): 47-55, 2023 Jan 25.
Article in English | MEDLINE | ID: covidwho-2235954
ABSTRACT
Toll-like receptor 4 (TLR4) is a reliable target for the development of vaccine adjuvants. To identify novel TLR4 ligands with improved immunological properties for use as adjuvants for a RBD-hFc based SARS-CoV-2 vaccine, herein, natural E. coli monophosphoryl lipid A (MPLA) and nine of its derivatives were designed and synthesized. Immunological evaluation showed that compounds 1, 3, 5 and 7 exhibited comparative or better adjuvant activity than clinically used Al adjuvants, and are expected to be a promising platform for the development of new adjuvants used for a RBD-hFc based SARS-CoV-2 vaccine. Preliminary structure-activity relationship analysis of the MPLA derivatives showed that the replacement of the functional groups at the C-1, C-4' or C-6' position of E. coli MPLA has an effect on its biological activity. In addition, we found that the combination of MPLA and Al was feasible for immunotherapy and could further enhance immune responses, providing a new direction toward the immunological enhancement of RBD-hFc based SARS-CoV-2 vaccines.

Full text: Available Collection: International databases Database: MEDLINE Type of study: Experimental Studies / Prognostic study / Randomized controlled trials Topics: Vaccines Language: English Journal: RSC Med Chem Year: 2023 Document Type: Article

Similar

MEDLINE

...
LILACS

LIS


Full text: Available Collection: International databases Database: MEDLINE Type of study: Experimental Studies / Prognostic study / Randomized controlled trials Topics: Vaccines Language: English Journal: RSC Med Chem Year: 2023 Document Type: Article